Patients received under-the-skin injections of the drug every three weeks, for a total of three immunizations. Results, published in a issue of the scientific journal Cancer Immunology and Immunotherapy, showed that ETBX stimulated significant CMI responses to CEA, even in patients who already had antibodies against adenovirus, and was safe and well-tolerated.
According to its authors, these results support ETBX advancing to a larger and randomized trial. This small, single-site trial also involves adults with locally advanced or metastatic CEA-expressing colon cancer that has returned after standard of care treatment.
The study began in April and is expected to finish collecting data in early Many other trials plan to test ETBX in combination with different immunotherapy and chemotherapy drugs for several different types of cancer, but most are not yet open for recruitment.
You're done! Now you can use those materials in your analysis. Click here for more detailed import instructions Detailed Instructions Register as a Premium member and then log in to MatWeb. Visit the Advanced Search interface or any search results page.
This is one place where users create and maintain Folders for exporting and comparing material data. Create a new Folder: The next step to the export process is to create a new Folder, or use the default "My Folder". You can create up to five folders with up to 20 data sheets per folder. You can name and populate these different folders based on a type of material, specific projects, or other systems that you find useful.
If you have previously created folders, then you can select them from this same interface. This example uses a search phrase of "gold. Check the boxes of the data sheets you wish to add to the active library. You may add up to 20 to each library, using the results of multiple searches. This example will continue using the ETBX viewing mode.
Note that from this page you can also add a comment, empty, or completely delete folders. Exclusion Criteria: Participation in an investigational drug or device study within 30 days of screening for this study. Pregnant and nursing women. Subjects with ongoing everolimus or other cancer therapy that interferes with the induction of immune responses. Subjects with concurrent cytotoxic chemotherapy or radiation therapy.
There must be at least one 1 month between any other prior chemotherapy or radiotherapy and study treatment. Any prior CEA-targeted immunotherapy vaccine must have been discontinued at least 3 months before initiation of study treatment. Subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study. Subjects with a history of autoimmune disease active or past , such as but not restricted to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis.
Autoimmune-related thyroid disease and vitiligo are permitted. Subjects with serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, or other illness considered by the Investigator as high risk for investigational drug treatment. Subjects with a medical or psychological impediment that would impair the ability of the subject to receive therapy per protocol or impact ability to comply with the protocol or protocol-required visits and procedures.
History of malignancy except for the following: adequately treated non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, or other carcinoma that has been in complete remission without treatment for more than 5 years. Subjects on systemic intravenous or oral steroid therapy or other immunosuppressives, such as azathioprine or cyclosporin A are excluded on the basis of potential immune suppression. Subjects must have had at least 6 weeks of discontinuation of any steroid therapy except that used as premedication for chemotherapy or contrast-enhanced studies prior to enrollment.
Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded. Subjects with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
Subjects vaccinated with a live attenuated vaccine e. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. More Information. National Library of Medicine U.
0コメント